Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
Find the Techniques for Powerful Review Propensities: Opening Your Scholarly Potential- ‘Slender Man’ attacker back in custody. What we know about Morgan Geyser's disappearance and what happens next.
- Landon Donovan knew he couldn’t hide his hair loss. So he turned to fans for help.
- The Effect of Online Organizations on Society: Beating the Difficulties
- What are parents to do as doctors clash with Trump administration over vaccines?
- Tragedy in Minnesota, vaccine news, Snoop's game call: Week in review
- It's official: NASA's Artemis 2 moon mission will break humanity's all-time distance record
- The Most Astonishing Arising Advancements to Watch
- Ancient meditation practices find new life in modern religious communities across America
